ACE2 overexpression or ACE2-Ang-(1–7)-MasR activation may reduce angiogenesis, either through the inhibition of VEGFα production in NSCLC, or downregulation of the expression of VEGFR in nasopharyngeal carcinoma, respectively [107,108]. Here, ACE2 is linked to non-small cell lung carcinoma.